Aspirin use linked to reduced cancer mortality risk in older adults


  • Dawn O'Shea
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

A secondary analysis of data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial suggests the use of aspirin ≥3 per month is associated with a reduction in all-cause and cancer mortality in older adults.

The cohort study examined trial data collected from 146,152 participants aged ≥65 years at baseline (1993-2001). Median follow-up was 12.5 years.

Compared with no use, aspirin use 1-3 times/month was associated with reduced risk of all-cause (HR 0.84; 95% CI 0.80-0.88; P<.001 and cancer ci p mortality particularly for gastrointestinal colorectal>

Aspirin use ≥3 times/week was associated with reductions in all-cause (HR 0.81; 95% CI 0.80-0.83; P<.001 cancer mortality ci p reductions in risk were greater participants with gastrointestinal and colorectal>

Among those with a BMI of 20-24.9 kg/m2, aspirin ≥3 times/week was associated with reductions in all-cause (HR 0.82; 95% CI 0.78-0.85; P<.001 and cancer ci p mortality. similar reductions were seen in those with bmi kg>2 group.

Dosage information was limited and therefore not included in the analysis.